Clinical information on the study participants
| Sample ID . | CD4/CD8 cells/μL at treatment initiation . | HIV RNA copies/mL at treatment initiation . | Initial treatment regimen . | Treatment modification . |
|---|---|---|---|---|
| 229 | 381/1224 | 147 000 | AZT/3TC/NFV | NFV/ddI/d4T/HDU |
| 233 | 800/1125 | 1735 | d4T/ddI/NFV/HDU | — |
| 243 | 588/1071 | 245 600 | d4T/ddI/NFV/HDU | — |
| 244 | 405/690 | 317 600 | d4T/ddI/NFV/HDU | — |
| 249 | 247/650 | 71 880 | d4T/ddI/NFV/HDU | — |
| 260 | 690/966 | 76 010 | d4T/ddI/NFV/HDU | — |
| 263 | 924/868 | NA | d4T/ddI/NFV/HDU | — |
| 264 | 925/1125 | < 500 | AZT/3TC/IDV | CBV/IDV |
| 277 | 1000/2280 | 94 550 | AZT/3TC/NFV | — |
| 278 | 288/636 | 157 100 | AZT/3TC/NFV | — |
| 283 | 364/676 | 34 210 | AZT/3TC/NFV | — |
| 285 | 510/465 | 31 110 | AZT/3TC/NFV | — |
| 286 | 493/799 | 19 410 | AZT/3TC/NFV | — |
| 290 | NA | 1 700 000 | AZT/3TC/NFV | — |
| 303 | 630/555 | 15 340 | AZT/3TC/NFV | — |
| Sample ID . | CD4/CD8 cells/μL at treatment initiation . | HIV RNA copies/mL at treatment initiation . | Initial treatment regimen . | Treatment modification . |
|---|---|---|---|---|
| 229 | 381/1224 | 147 000 | AZT/3TC/NFV | NFV/ddI/d4T/HDU |
| 233 | 800/1125 | 1735 | d4T/ddI/NFV/HDU | — |
| 243 | 588/1071 | 245 600 | d4T/ddI/NFV/HDU | — |
| 244 | 405/690 | 317 600 | d4T/ddI/NFV/HDU | — |
| 249 | 247/650 | 71 880 | d4T/ddI/NFV/HDU | — |
| 260 | 690/966 | 76 010 | d4T/ddI/NFV/HDU | — |
| 263 | 924/868 | NA | d4T/ddI/NFV/HDU | — |
| 264 | 925/1125 | < 500 | AZT/3TC/IDV | CBV/IDV |
| 277 | 1000/2280 | 94 550 | AZT/3TC/NFV | — |
| 278 | 288/636 | 157 100 | AZT/3TC/NFV | — |
| 283 | 364/676 | 34 210 | AZT/3TC/NFV | — |
| 285 | 510/465 | 31 110 | AZT/3TC/NFV | — |
| 286 | 493/799 | 19 410 | AZT/3TC/NFV | — |
| 290 | NA | 1 700 000 | AZT/3TC/NFV | — |
| 303 | 630/555 | 15 340 | AZT/3TC/NFV | — |
AZT indicates zidovudine; 3TC, lamivudine; NFV, nelfinavir; ddi, didanosine; d4T, stavudine; HDU, hydroxyurea; NA, not available; IDV, indinavir; and CBV, AZT and 3TC combined capsule.